Presentation
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. German Society of Rheumatology, (DGRh) 2017, Stuttgart, Germany, September 2017.
German Society of Rheumatology, (DGRh)
(2017)
Disciplines
Publication Date
September, 2017
Citation Information
S Hall, Philip Mease and et.al.. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis (PsA) through 3 Years: Efficacy and Safety Results from a Phase 3 Trial. German Society of Rheumatology, (DGRh) 2017, Stuttgart, Germany, September 2017." German Society of Rheumatology, (DGRh) (2017) Available at: http://works.bepress.com/philip-mease/224/